Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

RCT (n=509) found no statistically significant difference in median overall survival between doxorubicin plus olaratumab group vs the doxorubicin plus placebo (20.4 months vs 19.7 months, HR for death = 0.95, 95% CI 0.69-1.31).


Journal of the American Medical Association

Resource links: